CAMBRIDGE, Mass. (AP) _ Dicerna Pharmaceuticals Inc. (DRNA) on Thursday reported a loss of $23.8 million in its second quarter.
The Cambridge, Massachusetts-based company said it had a loss of 35 cents per share.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 32 cents per share.
The biopharmaceutical company posted revenue of $5.7 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $10.9 million.
Dicerna Pharmaceuticals shares have increased 29% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.78, a drop of roughly 4% in the last 12 months.